Skip to main content
. 2017 Oct 7;9:274–283. doi: 10.1016/j.omtn.2017.10.002

Table 3.

Demographic and Clinicopathological Parameters of HCC Patients with miR-135a Levels Higher or Lower in Tumor Than the Adjacent Normal Region

Variable Total miR-135a T > N
miR-135a T < N
p Value
n (%) n (%)
Atg14 mRNA Expression (T/N)
T > N 13 6 (46.2) 7 (53.8) p < 0.001
T < N 90 84 (93.3) 6 (6.7) p < 0.001

Age

≥50 years 85 74 (87.1) 11 (12.9) p = 0.832
<50 years 18 16 (88.9) 2 (11.1) p = 0.832

Sex

Male 82 72 (87.8) 10 (12.2) p = 0.797
Female 21 18 (85.7) 3 (14.3) p = 0.797

Cirrhosis

Present 61 52 (85.2) 9 (14.8) p = 0.432
Absent 42 38 (90.5) 4 (9.5) p = 0.432

Hepatitis

B 71 68 (95.8) 3 (4.2) p = 0.002
C 14 9 (64.3) 5 (35.7) p = 0.002
B + C 3 2 (66.7) 1 (33.3) p = 0.002
NBNC 15 11 (73.3) 4 (26.7) p = 0.002

HBs-Ag

Positive 74 70 (94.6) 4 (5.4) p < 0.001
Negative 29 20 (69) 9 (31) p < 0.001

Pathology Stage

I, II 69 57 (82.6) 12 (17.4) p = 0.038
III, IV 34 33 (97.1) 1 (2.9) p = 0.038

T_stage

1, 2 68 56 (82.4) 12 (17.6) p = 0.032
3, 4 35 34 (97.1) 1 (2.9) p = 0.032

N_stage

n0 101 88 (87.1) 13 (12.9) p = 0.587
n1 2 2 (100) 0 (0) p = 0.587

M_stage

n0 99 86 (86.9) 13 (13.1) p = 0.438
n1 4 4 (100) 0 (0) p = 0.438

Tumor Size

≥5 cm 51 44 (86.3) 7 (13.7) p = 0.738
<5 cm 52 46 (88.5) 6 (11.5) p = 0.738

Tumor Number

1 92 80 (87) 12 (13) p = 0.505
2 7 7 (100) 0 (0) p = 0.505
3 3 2 (66.7) 1 (33.3) p = 0.505
4 1 1 (100) 0 (0) p = 0.505

Recurrent

Present 63 60 (95.2) 3 (4.8) p = 0.003
Absent 40 30 (75) 10 (25) p = 0.003

Microvascular Invasion

Present 66 62 (93.9) 4 (6.1) p = 0.007
Absent 37 28 (75.7) 9 (24.3) p = 0.007

AFP

<70 ng/mL 65 53 (81.5) 12 (18.5) p = 0.02
≥70 ng/mL 38 37 (97.4) 1 (2.6) p = 0.02

mean (95% CI) mean (95% CI)

AST(U/L) 103 51.1 (40.9–61.2) 48.3 (28.6–68) p = 0.845
ALT(U/L) 103 52.2 (42.3–61.9) 59.4 (23–95.9) p = 0.612

T/N, tumor versus non-tumor adjacent tissue expression levels; HBs-Ag, hepatitis B virus surface antigen.